Related Experiment Video
Updated: Jul 7, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency
Kalyan Das1, Joseph D Bauman, Arthur D Clark
1Center for Advanced Biotechnology and Medicine and Department of Chemistry and Chemical Biology, Rutgers, The State University of New Jersey, Piscataway, NJ 08854, USA.
TMC278, a nonnucleoside reverse transcriptase inhibitor (NNRTI), effectively treats HIV-1 by adapting its structure to bind resistant viral reverse transcriptase (RT) through a flexible binding pocket. This structural flexibility is key to overcoming drug resistance mutations.
Area of Science:
- Structural Biology
- Virology
- Drug Discovery
Background:
- TMC278 is a potent diarylpyrimidine (DAPY) nonnucleoside reverse transcriptase inhibitor (NNRTI) effective against wild-type and drug-resistant HIV-1.
- Understanding the structural basis of TMC278's efficacy, especially against resistant strains, is crucial for optimizing HIV-1 treatment strategies.
Purpose of the Study:
- To determine the high-resolution crystal structures of wild-type and drug-resistant HIV-1 reverse transcriptase (RT) complexed with TMC278.
- To elucidate the molecular mechanisms by which TMC278 binds to both wild-type and mutant HIV-1 RT, including drug-resistant variants.
Main Methods:
- X-ray crystallography was employed to determine the structures of wild-type HIV-1 RT and mutant RTs (K103N/Y181C and L100I/K103N) in complex with TMC278.
- Systematic RT mutagenesis was used to engineer a suitable crystal form for high-resolution structure determination.
Main Results:
- High-resolution structures revealed TMC278's cyanovinyl group positioned in a hydrophobic tunnel connecting the NNRTI-binding pocket to the nucleic acid-binding cleft.
- TMC278 demonstrated adaptability to bind mutant RTs; in K103N/Y181C RT, interactions with Y183 compensated for Y181C mutation, facilitated by a Y(183)MDD motif shift.
- In L100I/K103N RT, TMC278's binding mode significantly altered to accommodate pocket changes induced by the L100I mutation, showcasing the binding pocket's 'shrink wrap' flexibility.
Conclusions:
- The flexible binding pocket of HIV-1 RT acts as a molecular 'shrink wrap,' adapting its shape to bind TMC278 effectively in both wild-type and drug-resistant forms.
- These crystal structures provide critical insights into how inhibitor flexibility can overcome drug-resistance mutations in HIV-1 RT, informing future drug design.
More Related Videos
10:50Assessment of Immunologically Relevant Dynamic Tertiary Structural Features of the HIV-1 V3 Loop Crown R2 Sequence by ab initio Folding
Published on: September 15, 2010
11:19Pairwise Growth Competition Assay for Determining the Replication Fitness of Human Immunodeficiency Viruses
Published on: May 4, 2015
Related Concept Videos
Size and Structure of Viral Genomes
Retrovirus Life Cycles
Viral Mutations
Inhibitors of Virion Maturation and Assembly
RNA Structure
Different Types of RNA Have the Same Basic Structure
There are three main types of ribonucleic acid (RNA) involved in protein synthesis: messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). All three...
Viruses with RNA Genomes